Innovation in Medicine and Health Care | Wednesday, May 18 3:00 pm – 5:00 pm
Robert C. Robbins, MD, President & CEO, Texas Medical Center
Dr. Arthur “Tim” Garson, Director, TMC Health Policy Institute
The past two decades have been marked by unparalleled advances in science and technology. In this century alone, the nation has witnessed a number of significant breakthroughs—most notably the recent cure for Hepatitis C and the advances in oncology, through new treatments based on new genetic understanding. But innovations are not limited to scientists and researchers. Innovation programs have proliferated across healthcare organizations and are tackling challenges including clinical quality, patient safety, access to care, health information technology, and much more. This panel will discuss how innovations are change the face of health care.
Disruptive Innovation | Thursday, May 19 10:00 am – 11:30 am
Dean Kamen, Innovator/Inventor
Lynda Chin, MD, Director, Institute for Health Transformation, University of Texas System
Disruptive innovation, a term of art coined by disruptive innovation theory pioneer Clayton M. Christensen, describes a process by which a product or service takes root initially in simple applications at the bottom of a market and then relentlessly moves up market, eventually displacing established competitors. Disruptive innovations enable new applications and changes in behaviors. They can come from entrepreneurial startups, university laboratories, government organizations, military projects and corporate R&D projects. If ever there was an industry in need of disruption, it is health care. Medical costs can be better contained and patient care can be improved. In this session you will hear from three leaders sharing their disruptive innovations.
The Promise and Perils of Precision Medicine | Friday, May 20 10:00 am – 11:30 am
Precision medicine holds great promise for improving the prevention, diagnosis and treatment of many diseases. Advances in Precision Medicine have already led to powerful new discoveries and several new treatments that are tailored to specific characteristics, such as a person’s genetic makeup, or the genetic profile of an individual’s tumor. As the number of effective targeted therapies grows, more patients are being assessed for genetic variations; indeed, some experts believe that sequencing a patient’s genome will soon be standard procedure. But there are many challenges being faced including enormous costs of treatment, regulatory, infrastructure, logistical, and ethical issues. This panel will explore the promise and perils of precision medicine.